Asset Details
Do you wish to reserve the book?
Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats
Do you wish to request the book?
Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats
2021
Overview
Morbidity and mortality risks are enhanced in preeclamptic (PE) mothers and their offspring. Here, we asked if sexual dimorphism exists in (i) cardiovascular and renal damage evolved in offspring of PE mothers, and (ii) offspring responsiveness to antenatal therapies. PE was induced by administering N
G
-nitro-L-arginine methyl ester (L-NAME, 50 mg/kg/day, oral gavage) to pregnant rats for 7 days starting from gestational day 14. Three therapies were co-administered orally with L-NAME, atrasentan (endothelin ETA receptor antagonist), terutroban (thromboxane A2 receptor antagonist, TXA2), or α-methyldopa (α-MD, central sympatholytic drug). Cardiovascular and renal profiles were assessed in 3-month-old offspring. Compared with offspring of non-PE rats, PE offspring exhibited elevated systolic blood pressure and proteinuria and reduced heart rate and creatinine clearance (CrCl). Apart from a greater bradycardia in male offspring, similar PE effects were noted in male and female offspring. While terutroban, atrasentan, or α-MD partially and similarly blunted the PE-evoked changes in CrCl and proteinuria, terutroban was the only drug that virtually abolished PE hypertension. Rises in cardiorenal inflammatory (tumor necrosis factor alpha, TNFα) and oxidative (isoprostane) markers were mostly and equally eliminated by all therapies in the two sexes, except for a greater dampening action of atrasentan, compared with α-MD, on tissue TNFα in female offspring only. Histopathologically, antenatal terutroban or atrasentan was more effective than α-MD in rectifying cardiac structural damage, myofiber separation, and cytoplasmic alterations, in PE offspring. The repair by antenatal terutroban or atrasentan of cardiovascular and renal anomalies in PE offspring is mostly sex-independent and surpasses the protection offered by α-MD, the conventional PE therapy.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Arginine
/ Atrasentan - administration & dosage
/ Biomedical and Life Sciences
/ Cardiovascular Diseases - etiology
/ Cardiovascular Diseases - prevention & control
/ Endothelin A Receptor Antagonists - administration & dosage
/ Endothelin A Receptor Antagonists - pharmacology
/ Female
/ Kidney Diseases - prevention & control
/ Kidneys
/ Male
/ Methyldopa - administration & dosage
/ Naphthalenes - administration & dosage
/ NG-Nitroarginine Methyl Ester
/ Pre-Eclampsia - drug therapy
/ Pre-Eclampsia - physiopathology
/ Propionates - administration & dosage
/ Rats
/ Receptors, Thromboxane A2, Prostaglandin H2 - antagonists & inhibitors
/ Sympatholytics - administration & dosage
